Aaron Gerds, MD, MS, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, discusses the initial results of the ongoing open-label, phase 2 trial evaluating luspatercept in patients with myelofibrosis (MF)-anemia (NCT03194542). The interim results suggest clinically significant activity of luspatercept in this group, including those receiving concomitant ruxolitinib. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.